NASDAQ · Biotechnology

JANX (JANX) Stock

$18.89 +3.68% NASDAQ: JANX Healthcare

Valuation

MetricValue
Price$18.89
Market Cap$1.15B
P/E Ratio-7.78
P/B Ratio0.91
P/S Ratio39.59
EPS (TTM)$-1.83
52-Week High$35.34
52-Week Low$12.12
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-11.91%
ROA-11.31%
ROCE-16.51%
Gross Margin-1580.00%
Operating Margin-1580.00%
Net Margin-5.30%
Debt/Equity0.02
Current Ratio39.04

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$9.0M$8.0M$11.0M$10.0M
Operating Profit$-33.0M$-67.0M$-73.0M$-99.0M$-158.0M
Net Profit$-33.0M$-63.0M$-58.0M$-69.0M$-114.0M
EPS$-0.79$-1.52$-1.32$-1.28$-1.83
Op Margin-905.4%-779.0%-902.9%-933.6%-1576.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$380.0M$364.0M$380.0M$1.1B$1.0B
Total Liabilities$13.0M$43.0M$36.0M$39.0M$51.0M
Cash$36.0M$51.0M$19.0M$431.0M$52.0M
Borrowings$0$25.0M$25.0M$23.0M$22.0M

Latest News

Is Janux Therapeutics’ (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story? Simply Wall St. · Jul 9, 2026 VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone Exec Edge · Jul 2, 2026 Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential? Insider Monkey · Jun 30, 2026 Akari Therapeutics Highlights 1st ASCO Abstract Acceptance IPO-Edge.com · May 28, 2026 VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC Exec Edge · May 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-17.0M$-43.0M$-51.0M$-44.0M$-82.0M
Investing Cash Flow$-342.0M$52.0M$-43.0M$-258.0M$-302.0M
Financing Cash Flow$2.0M$0$3.0M$15.0M$0
Net Cash Flow$29.0M$16.0M$-32.0M$411.0M$-378.0M
Free Cash Flow$-18.0M$-49.0M$-52.0M$-44.0M$-83.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-9.17%
Quick Ratio17.01
Interest Coverage—
Return 1Y-40.59%
Return 3Y15.25%
Return 5Y-41.10%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABCL $11.28 -1.74% -21.26 $3.44B 0.00%
BHVN $15.74 +3.08% -6.11 $2.37B 0.00%
CLDX $39.24 -0.98% -7.84 $2.61B 0.00%
HRMY $41.25 +4.75% 11.23 $2.39B 0.00%
IMNM $27.07 -1.26% -8.13 $2.59B 0.00%

About JANX

JANX is led by CEO David Alan Campbell, employs 91 people, headquartered in US, publicly traded since 2021.

JANX stock trades at $18.89 with a market capitalization of $1.15B. The stock is valued at a price-to-earnings (P/E) ratio of -7.78, price-to-book of 0.91, price-to-sales of 39.59. Over the past 52 weeks the stock has ranged between $12.12 and $35.34, and currently trades 46.5% below its 52-week high.

On profitability, JANX generates a return on equity (ROE) of -11.91%, return on capital employed of -16.51%, an operating margin of -1580.00%, a net profit margin of -5.30%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides